Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.

You may also be interested in...



CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming

Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.

Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics

Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.

Tie Goes To The Nominee: Becerra Heads To Senate Floor

Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel